The Expression And Significance Of Dyrk1B In The Specimens And Cells Of Ovarian Cancer

Objective: To examine the expression of Dyrk1 B in the specimens and cells of ovarian cancer. To determine the effect of Dyrk1 B inhibitor AZ191 on cellular proliferation, apoptosis, and the expression of Dyrk1 B protein in ovarian cancer cells. To explore the role of Dyrk1 B in the occurrence and development of ovarian cancer.Methods:(1) Western blot was used to determine the expression of Dyrk1 B proteins in OVCAR8, OVCAR5, OVCAR4, OVC AR3, SKOV3, OV2008, C13, A2780 S, and A2780 CP cells, also in the O V2008 and A2780 CP cells treated with AZ191.(2) MTT assay was used to determine the influence of AZ191 on the growth of OV2008, C13, A2780 S, and A2780 CP cells.(3) Flow cytometry was used to determine the influence of AZ191 on apoptosis of OV2008, C13, A2780 S, and A2780 CP cells.(4) Immunohistochemistry was utilized to detect Dyrk1 B expression in the specimens of ovarian cancer.Results:(1) Dyrk1 B is expressed in the cells of OVCAR8, OVCAR5, OVCAR4, OVCAR3, SKOV3, OV2008, C13, A2780 S, and A2780 CP. Dyrk1 B protein of ovarian cancer cells(O V2008 and A2780CP) was reduced significantly by Western blot after treatment of AZ191 for 48 h.(2) The cellular proliferation of ovarian cancer cells(OV2008, C13, A2780 S, and A2780CP) was significantly inhibited in a concentration-dependent manner after 48h-treatment of Dyrk1 b inhibitor AZ191 assayed by MTT( P<0.05).(3) The cell apoptosis of ovarian cancer cells(OV2008, C13, A2780 S, and A2780CP) analyzed by Flow cytometry was significantly increased by AZ191 dose-dependently.(4) Immunohistochemical results: The clinical data of 119 patients with ovarian cancer and 19 patient with normal ovarian taken as normal control were analyzed, respectively. The 119 cases of ovarian cancer which was included 77 cases of serous carcinoma, 17 cases of mucinous carcinoma, 15 cases of endometrial carcinoma, and 10 cases of clear cell carcinoma. The immunohistochemical results showed that Dyrk1 B was overexpressed in ovarian cancer with the expression rate 90.8%(108/119), compared with normal ovarian tissue with the expression rate 15.7%(3/19), which exhibited statistically significant difference(P = 0.000). But, there was no any correlation between the Dyrk1 B protein expression and the pathologic grade or the clinical stage(P > 0.05).Conclusion: Dyrk1 B is overexpressed in both the specimens and cells of ovarian cancer. AZ191, an inhibitor of Dyrk1 B, can inhibit cellular proliferation and induce apoptosis of ovarian cancer cells accompanied by decreased Dyrk1 B protein expression. All together, our study suggests that Dyrk1 B play an important role in the tumorigenesis and development of ovarian cancer, and it may serve as important therapeutic target for the patients.